Four technology appraisals (TAs) have been published by NICE, detailing evidence-based recommendations regarding whether the following drugs should be used for the specified indication:
- TA440—Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
- TA441—Daclizumab for treating relapsing–remitting multiple sclerosis
- TA442—Ixekizumab for treating moderate to severe plaque psoriasis
- TA443—Obeticholic acid for treating primary biliary cholangitis.
NICE TAs assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, as well as procedures, devices, and diagnostic agents. If the TA recommends a treatment as an option, the NHS must make sure it is available within 3 months (unless otherwise specified) of the TA publication date.